Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers

11 October 2018

There is a concrete risk that disproportionate influence on the […]

CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court

20 September 2018

An English Court has determined that the contested supplementary protection […]

SPC manufacturing waiver is good news for Europe

19 September 2018

An SPC manufacturing waiver should be extremely beneficial for Europe […]

SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform

17 September 2018

Medicines for Europe welcomes the European Parliament’s Committee on Environment, […]

Analysis of the proposal for a regulation of a manufacturing exception related to the SPC and aimed to make the European industry competitive

13 September 2018

Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community

22 June 2018

Medicines for Europe is committed to bringing accessible, high quality […]

Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

14 June 2018

The joint 24th Medicines for Europe and 21st IGBA Annual […]

Andriukaitis: SPC manufacturing waiver does not damage pharma innovation

12 June 2018

IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly

7 June 2018

Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe

28 May 2018

Medicines for Europe commends the European Commission for proposing an […]